Atlas Trials

Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone

Clinical trial NCT03978832 · COMPLETED

Trial details

NCT number
NCT03978832
Sponsor
Indivior Inc.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Schizophrenia
Start date
2019-06-28
Primary completion
2020-05-12
Enrollment
69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.